South Korea Biologics Safety Testing Market (2026-2031)
The South Korea Biologics Safety Testing Market was valued at $43.1 Million in 2026 and projected to reach to $76.7 Million by 2031, representing a compound annual growth rate of 12.2%. South Korea's biologics safety testing market is positioned for sustained growth through 2031, driven by the country's emergence as a competitive biopharmaceutical manufacturing and development hub.
South Korea Biologics Safety Testing Market Trends and Insights
- This growth trajectory reflects South Korea's strengthening position as a biopharmaceutical hub in Asia Pacific, driven by increasing regulatory scrutiny, rising biologics development pipelines, and heightened investment in quality assurance infrastructure.
- South Korea's advanced healthcare ecosystem and stringent regulatory frameworks are accelerating demand for comprehensive safety testing services across therapeutic biologics, biosimilars, and novel biologics candidates. The 12.2% compound annual growth rate underscores South Korea's commitment to maintaining competitive standards in global biologics manufacturing and development.
- South Korea's pharmaceutical sector is increasingly adopting advanced safety testing methodologies, including in vitro and in vivo assays, to meet both domestic and international regulatory requirements.
- By 2031, South Korea is expected to consolidate its role as a critical testing and validation center, supported by expanding contract research organization (CRO) capabilities and growing collaboration between academic institutions and industry stakeholders..
Key Market Statistics
- CAGR (2026-2031) 12.2% CAGR
- Market Size, 2026 ~USD 43.1 Million
- Forecast, 2031 ~USD 76.7 Million
- Country South Korea
South Korea Biologics Safety Testing Market Overview
Rapid Market Expansion :
South Korea's biologics safety testing market is projected to grow from $43.1 million in 2026 to $76.7 million by 2031, representing a robust 12.2% CAGR, outpacing the global average of 11.6%.
Asia Pacific Biopharmaceutical Hub :
South Korea is establishing itself as a leading biopharmaceutical development center in Asia Pacific, with increasing investments in biologics manufacturing and quality assurance infrastructure.
Regulatory Compliance Drivers :
Heightened regulatory scrutiny from South Korean authorities and alignment with international standards are compelling biopharmaceutical companies to invest significantly in comprehensive safety testing protocols.
Growing Development Pipelines :
South Korea's expanding biologics development pipelines, driven by domestic and international pharmaceutical companies, are creating sustained demand for specialized safety testing services and capabilities.
South Korea Biologics Safety Testing Market Dynamics
- The market benefits from strong government support for biotech innovation, increasing foreign direct investment, and a highly skilled workforce specializing in pharmaceutical quality assurance.
- Regulatory harmonization with global standards and the expansion of contract research organizations (CROs) are accelerating market development. The forecast period will see intensified competition among testing service providers, with opportunities for specialized niche players focusing on advanced testing methodologies.
- South Korean companies are increasingly adopting cutting-edge safety testing technologies, including in vitro and in silico approaches, to reduce development timelines and costs.
- Strategic partnerships between domestic firms and international biopharmaceutical companies will further propel market expansion and technological advancement..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Key Takeaways
- South Korea's biologics safety testing market will grow from $43.1M (2026) to $76.7M (2031) at a 12.2% CAGR.
- South Korea's regulatory environment and biopharmaceutical infrastructure are driving increased demand for advanced safety testing services.
- South Korea's expanding CRO sector and academic-industry partnerships are strengthening local testing capabilities and competitiveness.
- South Korea is positioned as a critical Asia Pacific hub for biologics validation, supporting both domestic and international clients.
Biologics Safety Testing Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | STERILITY TESTING SERVICES (Application) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 11.6% from 2026 to 2031 |
| Largest Segment | SERVICES (Offering) |
| Market Size Base Year (Billions) | ~USD 5.58 (2026) |
| Revenue Forecast (Billions) | ~USD 9.66 (2031) |
| Segments Covered | Offering, Type, Product & Service, Test Type, Application, End User |
South Korea Biologics Safety Testing Market Report Segmentation
6 segment dimensions are covered across the global market.
By Offering
- Products
- Services
By Type
- Bioburden Testing Services
- Endotoxin Testing Services
- Mycoplasma Testing Services
- Other Biologics Safety Testing Services
- Other Bst Services
- Sterility Testing Services
- Virus Safety Testing Services
By Product & Service
- Consumables
- Instruments
- Services
By Test Type
- Bioburden Tests
- Endotoxin Tests
- Mycoplasma Tests
- Other Biologics Safety Tests
- Residual Host Cell Proteins & Dna Detection Tests
- Sterility Tests
- Virus Safety Tests
By Application
- Blood & Blood Products Development And Manufacturing
- Cellular & Gene Therapy Products Development And Manufacturing
- Monoclonal Antibodies Development And Manufacturing
- Other Applications
- Vaccines Development And Manufacturing
By End User
- Academic & Research Institutes
- Cros & Cdmos
- Pharmaceutical & Biotechnology Companies
Target Audience
- Biopharmaceutical Manufacturers : South Korean and international biotech companies developing biologics require detailed market data to optimize safety testing investments, select service providers, and navigate local regulatory pathways.
- Contract Research Organizations (CROs) : CROs operating in or entering South Korea need market intelligence to benchmark service offerings, identify growth opportunities, and understand competitive positioning within the expanding testing services market.
- Regulatory & Quality Assurance Teams : Compliance and quality professionals in South Korean pharmaceutical companies require insights into evolving safety testing standards, regulatory expectations, and best practices for biologics development.
- Healthcare Investors & Private Equity : Investment firms evaluating opportunities in South Korea's biotech sector need comprehensive market data to assess growth potential, valuation benchmarks, and strategic acquisition targets in safety testing.
- Laboratory Equipment & Technology Providers : Suppliers of testing equipment, software, and analytical technologies need market forecasts and demand drivers to identify sales opportunities and develop solutions tailored to South Korean market requirements.
Key Companies in the South Korea Biologics Safety Testing Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| PATHEON INC | Netherlands | Private Company | Drug Product Services (finished dosage manufacturing, packaging, lifecycle management),Pharmaceutical Development Services (formulation, clinical trial supply),Drug Substance Services (API and biologics substance), |
| SIGMA-ALDRICH CORPORATION | United States | Private Company | Chemicals and Biochemicals Catalog,Cell Culture, Media, and Critical Raw Materials,Filtration, Labware, and Water Purification, |
| WUXI PHARMATECH (CAYMAN) INC | China | Private Company | Chemistry drug CRDMO services,Biology discovery and preclinical testing,Clinical research services, |
| FLUOR CORPORATION | United States | Public Company | Energy Solutions (oil, gas, chemicals, LNG, power, energy transition),Urban Solutions (advanced technologies, life sciences, mining, infrastructure, staffing, maintenance),Mission Solutions (government, nuclear remediation, security, logistics, O&M), |
| AZELIS HOLDINGS SA | Belgium | Private Company | Coatings, Plastics & Advanced Materials Specialties,Food & Nutrition Ingredients,Personal Care & Home Care Ingredients, |
| CATALENT, INC. | United States | Private Company | Biologics (proteins, cell and gene, parenteral, large-molecule analytics),Pharma and Consumer Health – softgels and advanced oral dose (incl. Zydis),Pharma and Consumer Health – other oral, nasal, inhaled, topical, |
PATHEON INC
Patheon Inc. is a Netherlands-based private company with 9,100 employees operating in the pharmaceutical and biotechnology services sector.
SIGMA-ALDRICH CORPORATION
Sigma-Aldrich Corporation is a United States-based private company founded in 1951 with 9,800 employees specializing in life science and chemical products.
WUXI PHARMATECH (CAYMAN) INC
Wuxi Pharmatech (Cayman) Inc. is a China-based private company founded in 2000 with 8,837 employees providing pharmaceutical research and development services.
FLUOR CORPORATION
Fluor Corporation is a United States-based public company founded in 1912 with 22,995 employees operating in engineering, procurement, and construction services.
AZELIS HOLDINGS SA
Azelis Holdings SA is a Belgium-based private company founded in 2001 with 1,325 employees specializing in specialty chemicals and ingredients.
CATALENT, INC.
Catalent, Inc. is a United States-based private company founded in 1933 with 16,900 employees offering pharmaceutical development and manufacturing services.
Reasons to Buy this Report
- Market-Specific Growth Intelligence : Gain detailed insights into South Korea's 12.2% CAGR trajectory and understand the unique drivers differentiating this market from global trends, enabling targeted investment and expansion strategies.
- Competitive Landscape Analysis : Identify key players, service providers, and emerging competitors within South Korea's biologics safety testing ecosystem to inform partnership, acquisition, and market entry decisions.
- Regulatory & Compliance Roadmap : Understand South Korea-specific regulatory requirements, quality standards, and compliance frameworks that impact testing protocols and service delivery for biologics development.
- Investment Opportunity Assessment : Evaluate market sizing, growth projections through 2031, and capital allocation opportunities within South Korea's expanding biopharmaceutical infrastructure and testing services sector.
- Strategic Partnership Identification : Discover potential collaboration opportunities with South Korean CROs, testing laboratories, and biopharmaceutical companies to accelerate market penetration and service expansion.
Frequently asked questions
What is the current size of South Korea's biologics safety testing market?
South Korea's biologics safety testing market was valued at $43.1 million in 2026 and is projected to reach $76.7 million by 2031.
What is driving growth in South Korea's biologics safety testing market?
Growth in South Korea is driven by increasing regulatory requirements, expanding biologics development pipelines, rising investment in quality assurance, and the country's position as a biopharmaceutical hub in Asia Pacific.
What is the CAGR for South Korea's biologics safety testing market?
South Korea's biologics safety testing market is growing at a compound annual growth rate of 12.2% from 2026 to 2031.
Which testing methodologies are most prevalent in South Korea?
South Korea's pharmaceutical sector increasingly adopts in vitro and in vivo assays, along with advanced safety testing methodologies to meet domestic and international regulatory standards.
How is South Korea positioned in the Asia Pacific biologics testing landscape?
South Korea is consolidating its role as a critical testing and validation center in Asia Pacific, supported by expanding CRO capabilities, advanced healthcare infrastructure, and growing academic-industry collaboration.
RESEARCH METHODOLOGY
This study involved four major activities in estimating the current size of the biologics safety testing market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the US Food and Drug Administration (FDA), World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Center for Biotechnology Information (NCBI), Organisation for Economic Co-operation and Development (OECD), National Institutes of Health (NIH), News Articles, Press Releases. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global biologics safety testing market, and the findings were validated through primary research.
Primary Research
In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the biologics safety testing market was estimated through multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.
Market Definition
The biological safety testing market comprises the products and services used to assess the safety, purity, potency, and quality of biologically derived products across their development, manufacturing, and release stages.
Key Stakeholders
- Biologics safety testing products and services companies
- National and regional research boards and organizations
- Research & development companies
- Clinical research organizations (CROs)
- Biotechnology companies
- Research laboratories & academic institutes
- Market research & consulting firms
- Regulatory bodies
Report Objectives
- To define, describe, and forecast the biologics safety testing market by offering, test type, product application, service application, product end user, service end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall biologics safety testing market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC (Saudi Arabia (KSA), United Arab Emirates (UAE), and the Rest of GCC) and the Rest of Middle East], and Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy.
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographical Analysis
- Further breakdown of the Rest of Europe biologics safety testing market, by country
- Further breakdown of the Rest of Asia Pacific biologics safety testing market, by country
Company Information
- Detailed analysis and profiling of additional market players (up to five)
Segment Analysis
- Cross-segment analysis
Get the Full Biologics Safety Testing Market Report
Full forecast, segment splits, and company analysis for all Biologics Safety Testing Market.
- US Biologics Safety Testing Market
- Canada Biologics Safety Testing Market
- UK Biologics Safety Testing Market
- Germany Biologics Safety Testing Market
- France Biologics Safety Testing Market
- Italy Biologics Safety Testing Market
- Spain Biologics Safety Testing Market
- China Biologics Safety Testing Market
- Japan Biologics Safety Testing Market
- India Biologics Safety Testing Market
- Australia Biologics Safety Testing Market
- Brazil Biologics Safety Testing Market
- Mexico Biologics Safety Testing Market
- Saudi Arabia Biologics Safety Testing Market
- UAE Biologics Safety Testing Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report